Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Cambrex Corporation (NYSE: CBM) shares dropped 14.16 percent to close at $19.04 a share Tuesday. The stock traded between $17.86 and $20.25 on volume 2.85 million shares traded. The company’s 2014 forecast of EPS of $0.99-$1.10 on sales growth of 8%-12% fell short of expectations. Shares of Cambrex are up approximately 6.0 percent year-to-date.
Get more information on Cambrex free access to the in-depth equity report at:
InvenSense Inc. (NYSE: INVN) shares jumped 10.78 percent to close at $21.69 a share Tuesday. The stock traded between $20.61 and $22.09 on volume of 7.07 million shares traded. The company announced a patent settlement with STMicroelectronics. Robert W. Baird has raised its price target on the company to $23.00 from $20.00. Shares of InvenSense are up approximately 4.0 percent year-to-date.
Get more information on InvenSense and free access to the in-depth equity report at:
TriQuint Semiconductor (NASDAQ: TQNT) shares spiked 11.39 percent to close at $9.42 a share Tuesday. The stock traded between $8.39 and $9.44 on volume of 11.61 million shares traded. According to a recent report from Forbes, the company has retained Goldman Sachs for advice related to the pressure it is facing from hedge fund Starboard Value. Shares of TriQuint Semiconductor are up approximately 12.0 percent year-to-date.
Get more information on TriQuint Semiconductor and free access to the in-depth equity report at:
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares surged 12.04 percent to close at $4.56 a share Tuesday. The stock traded between $4.11 and $4.62 on volume 1.76 million shares traded. The company recently presented at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th. Shares of ZIOPHARM Oncology are up approximately 5.0 percent year-to-date.
Get more information on ZIOPHARM Oncology and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities